期刊
CURRENT PHARMACEUTICAL BIOTECHNOLOGY
卷 20, 期 5, 页码 366-375出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1389201020666190417124711
关键词
Fenoldopam mesylate; post-operative acute kidney injury; contrast-induced nephropathy; Intensive care unit-acute kidney injury; DA-1 receptor; dopamine; chronic kidney disease
资金
- Federazione Medico Sportiva Italiana
Background: Fenoldopam mesylate is a selective agonist of DA-1 receptors. It is currently used for the in-hospital treatment of severe hypertension. DA-1 receptors have high density in renal parenchyma and for this reason, a possible reno-protective role of Fenoldopam mesylate was investigated. Methods: We examined all studies regarding the role of Fenoldopam mesylate in Acute Kidney Injury (AKI); particularly, those involving post-surgical patients, intensive care unit patients and contrast-induced nephropathy. Results: Fenoldopam mesylate was found to be effective in reducing the onset of postoperative AKI, when used before the development of the kidney damage. Positive results were also obtained in the management of intensive care unit patients with AKI, although the clinical studies investigated were few and conducted on small samples. Conclusion: Conflicting results were achieved in contrast-induced nephropathy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据